ViferaXS
Biotechnology company developing peptide-based T cell activator immunotherapies for cancer and infectious diseases. Operates an immunopeptidome-based antigen discovery platform to identify naturally presented tumor peptides and composes off-the-shelf vaccine candidates. Works on adjuvant formulations to induce durable T cell responses and advances programs through clinical translation.
Industries
Nr. of Employees
small (1-50)
Products
Off-the-shelf peptide-based therapeutic vaccines (T cell activators)
Therapeutic candidates composed of peptide antigens and adjuvant formulations designed to activate tumor-directed T cell responses; developed as off-the-shelf compositions using a tumor antigen repository.
Off-the-shelf peptide-based therapeutic vaccines (T cell activators)
Therapeutic candidates composed of peptide antigens and adjuvant formulations designed to activate tumor-directed T cell responses; developed as off-the-shelf compositions using a tumor antigen repository.
Services
Analysis of patient tumor-presented peptides to identify tumor-specific antigens for therapeutic composition; offered for collaboration from early discovery to clinical development.
Analysis of patient tumor-presented peptides to identify tumor-specific antigens for therapeutic composition; offered for collaboration from early discovery to clinical development.
Expertise Areas
- Immunopeptidomics
- Peptide vaccine development
- Adjuvant formulation
- Translational immunology
Key Technologies
- Immunopeptidome analysis
- Neoepitope discovery
- Peptide-based vaccine platforms
- Adjuvant formulation for T cell activation
News & Updates
Company states it has a program at Phase II readiness targeting CLL.
Founding clinical team reports four ongoing clinical trials evaluating in-house developed peptide-based T cell activators.
Company states it has a program at Phase II readiness targeting CLL.
Founding clinical team reports four ongoing clinical trials evaluating in-house developed peptide-based T cell activators.